Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 31,857

Document Document Title
WO/2017/011920A1
There are provided compounds, their preparation and their use in the treatment of medical conditions including cancers and immune disorders.  
WO/2017/014546A1
The present invention relates to a luminescent material for delayed fluorescence and an organic electroluminescent device comprising the same. By using the luminescent material for delayed fluorescence according to the present invention,...  
WO/2017/013865A1
The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]fura...  
WO/2017/012965A1
The invention relates to substituted heteroaryl carboxylic acid hydrazides of general formula (I) or salts thereof, wherein the groups of formula (I) have the definitions stated in the description, for increasing the stress tolerance in ...  
WO/2017/012842A1
The present invention relates to a process forpreparingfuran-2,5-dicarboxylic acid, comprising the following steps: preparing or providing a starting mixture comprising5-(hydroxymethyl)furfural (HMF),5,5'-[oxy-bis(methylene)]bis-2-furfur...  
WO/2017/013496A1
The compound (-)-tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride ((-)-ANAVEX2-73, (-)A2-73, (-)AE 37) has been found to exhibit selectivity for sigma-1 (σ1) receptors and stronger agonist activity at the muscarinic...  
WO/2017/013265A1
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...  
WO/2017/013498A3
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO/2017/013498A2
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characteriz...  
WO2017008681A1
The present invention relates to an amide derivative, and the preparation method and pharmaceutical use thereof. In particular, the present invention relates to the amino derivative as represented by general formula (I), the preparation ...  
WO2017009217A1
The invention is directed to a levulinic acid composition A comprising: a. at least 95wt% of levulinic acid; b. between 5 wppm and 5000 wppm of formic acid; and c. less than 1000 wppm of angelica lactone, based on the total weight of the...  
WO/2017/010626A1
The present invention relates to: a compound for an organic optoelectronic device, comprising a combination of a moiety represented by chemical formula I and a moiety represented by chemical formula II; an organic optoelectronic device c...  
WO2017009205A1
The present invention relates to a method for the regioselective hydroformylation of polyunsaturated acyclic hydrocarbons, which are 1, 3 butadienes, which, in the 2 position, bear a saturated or monounsaturated or polyunsaturated acycli...  
WO/2017/010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO/2017/010596A1
The present invention relates to: a protein having transglucosylation activity specific to carbon 3 of ascorbic acid; a composition for producing a vitamin C derivative; a compound represented by chemical formula 1 and produced by the pr...  
WO/2017/006296A1
Compounds of Formulas (I) and (II) and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.  
WO/2017/003294A1
A furfural derivative having the chemical formula (1) (1) wherein R represents hydrogen, an alkyl group or an acyl group, is prepared in a process, which process comprises reacting a fructose-and/or glucose-containing starting material w...  
WO/2017/004349A3
The present invention provides methods for the production of terephthalic acid and derivatives thereof using ethylene oxide, carbon monoxide and furan as feedstocks. The process is characterized by high yields and high carbon efficiency....  
WO/2017/001376A1
The present invention provides a method for increasing the molar ratio of tetrahydrofuran to 1,4-butanediol in a process for the production of 1,4-butanediol and tetrahydrofuran, said process comprising contacting furan with hydrogen and...  
WO/2017/003293A1
A furfural derivative having the chemical formula (1) wherein R represents hydrogen, an alkyl group or an acyl group, is prepared in a process, which process comprises reacting a fructose- and/or glucose-containing starting material with...  
WO/2017/003188A1
The present invention relates to: a novel compound which has an outstanding luminescent ability; and an organic electroluminescent element having improved properties including high luminous efficiency, low drive voltage and long lifespan...  
WO/2017/004349A2
The present invention provides methods for the production of terephthalic acid and derivatives thereof using ethylene oxide, carbon monoxide and furan as feedstocks. The process is characterized by high yields and high carbon efficiency....  
WO/2016/207025A1
Described is a method that involves synthesizing a mixture containing 5-hydroxmethylfurfural (HMF, compound of formula (I)), and separating 5-hydroxymethylfurfural from the obtained mixture. The disclosed method involves step (A), synthe...  
WO/2016/208862A1
The present invention provides: a compound which can implement the low driving voltage, high light-emitting efficiency and high heat resistance of an element, and improve the color purity and lifespan of the element; an organic electric ...  
WO/2016/207365A1
The invention relates to a method for continuously producing 5-hydroxymethylfurfural (referred to as HMF below, a compound of the formula (I)) in a reactor arrangement, having the following steps: - setting reaction conditions in a mixtu...  
WO/2016/207217A1
Compounds of formula (I); wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicaments.  
WO/2016/206909A1
The present invention relates to a process for preparing 5-hydroxymethylfurfural (also referred to hereinafter as "HMF", compound of the formula (I)) and humins, comprising steps (a), (b), (c), (d), (e) and (f) (cf. figure 1 and the appe...  
WO/2016/205202A1
The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertensi...  
WO/2016/205539A1
Disclosed herein are methods of inducing sperm deformation. In certain embodiments, the method includes contacting a sperm with an effective amount of triptonide, thereby inhibiting sperm motility. Also disclosed herein are methods of co...  
WO/2016/202965A1
The present invention relates to a novel method for preparing pantolactone by reacting hydroxypivalaldehyde cyanohydrin in a phase separation method.  
WO/2016/203402A1
The design and synthesis of a novel bis-furan scaffold tailored for high efficiency at inhibiting transthyretin amyloid formation is reported. In vitro results show that the discovered compounds are more efficient inhibitors of amyloid f...  
WO/2016/199784A1
A compound represented by formula (1) is a material which enables the achievement of an organic electroluminescent element having a long service life and being able to be driven at a low voltage. (In formula (1), R1-R4, a-d, L0-L2 and Ar...  
WO/2016/199906A1
The purpose of the present invention is to provide a novel low-molecular-weight compound which exhibits orexin receptor agonist activity and is expected to be useful as a prophylactic agent or therapeutic agent for narcolepsy and the lik...  
WO/2016/199172A3
The present invention disclosed a novel compound of formula (I), (II) and (III) and process for preparation thereof. Further, the present invention provides a pharmaceutical composition comprising compound of formula (I) or (II) or (III)...  
WO/2016/198507A1
Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing C6 heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected fro...  
WO/2016/199743A1
The present invention provides an arylamine compound represented by general formula (1). The arylamine compound according to the present invention is a novel compound, and has higher hole mobility than conventional hole transport materia...  
WO/2016/198374A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2016/197398A1
Disclosed are a sulfonic acid inner salt compound of amidine and a preparation method therefor. The product of a sulfonic acid inner salt of amidine is obtained and synthesized by adopting an o-aminobenzenesulfonyl chloride compound and ...  
WO/2016/198744A1
The invention relates to a method and an apparatus for producing a chemical compound from biomass based raw material. According to the invention, the biomass based raw material (1) is gasified in a gasification device (2) for forming a g...  
WO/2016/199789A1
The present invention addresses the problem of efficiently synthesizing a trifluoromethyl substituted semisquarate in a short process, in order to manufacture trifluoromethyl compounds with various functionalities. A method was developed...  
WO/2016/194901A1
Provided is a method for producing furfural, which enables furfural to be produced at higher yields from biomass starting materials containing hemicellulose. In this method for producing furfural, after contacting the biomass starting ma...  
WO/2016/191872A1
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also...  
WO/2016/195499A1
A purified acid composition comprising 2,5-furandicarboxylic acid is prepared by a process comprising a) providing an acid composition solution of a crude acid composition in a polar solvent, the crude acid composition comprising 2,5-fur...  
WO/2016/195077A1
This novel guanidine compound having excellent bactericidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R7-R9 independently represents a hydrogen ato...  
WO/2016/195115A1
A supported catalyst for aldehyde coupling reaction, comprising a carrier having supported thereon a catalyst comprising at least one azolium compound selected from the group consisting of a thiazolium salt, an imidazolium salt, a benzim...  
WO/2016/195361A1
The present invention provides: a novel benzylidene dihydroindenone derivative; and a composition for preventing or treating inflammatory bowel disease, containing the same. The benzylidene dihydroindenone derivative maintains the thickn...  
WO/2016/193822A1
A process for preparing (E)-(5,6-dihydro-l,4,2-dioxazin-3-yl)(2- hydroxyphenyl)methanone O-methyl oxime is described which includes: (i) reacting benzofuran-3(2H)-one O-methyl oxime (1) with at least one nitrite selected from n-butyl nit...  
WO/2016/193459A1
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases such as autoimmu...  
WO/2016/192631A1
The present invention provides an abietane-type diterpene compound having lipid-lowering activity, a method for preparing same, and use of same. Specifically, the compound has the structure shown in formula I. The definitions of the grou...  
WO/2016/193332A1
Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.The analogues are of formula (I) or (II):  

Matches 351 - 400 out of 31,857